Do You Know What BioSpecifics Technologies Corp.’s (NASDAQ:BSTC) P/E Ratio Means?

Today, we’ll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical, we’ll show how BioSpecifics Technologies Corp.’s (NASDAQ:BSTC) P/E ratio could help you assess the value on offer. Based on the last twelve months, BioSpecifics Technologies’s P/E ratio is 19.39. That corresponds to an earnings yield of approximately 5.2%.

View our latest analysis for BioSpecifics Technologies

How Do You Calculate A P/E Ratio?

The formula for P/E is:

Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Or for BioSpecifics Technologies:

P/E of 19.39 = $58.73 ÷ $3.03 (Based on the year to June 2019.)

Is A High Price-to-Earnings Ratio Good?

The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. That is not a good or a bad thing per se, but a high P/E does imply buyers are optimistic about the future.

Does BioSpecifics Technologies Have A Relatively High Or Low P/E For Its Industry?

The P/E ratio indicates whether the market has higher or lower expectations of a company. You can see in the image below that the average P/E (19.4) for companies in the biotechs industry is roughly the same as BioSpecifics Technologies’s P/E.

NasdaqGM:BSTC Price Estimation Relative to Market, August 18th 2019
NasdaqGM:BSTC Price Estimation Relative to Market, August 18th 2019

Its P/E ratio suggests that BioSpecifics Technologies shareholders think that in the future it will perform about the same as other companies in its industry classification.

How Growth Rates Impact P/E Ratios

P/E ratios primarily reflect market expectations around earnings growth rates. That’s because companies that grow earnings per share quickly will rapidly increase the ‘E’ in the equation. Therefore, even if you pay a high multiple of earnings now, that multiple will become lower in the future. Then, a lower P/E should attract more buyers, pushing the share price up.

BioSpecifics Technologies’s earnings made like a rocket, taking off 53% last year. The cherry on top is that the five year growth rate was an impressive 35% per year. So I’d be surprised if the P/E ratio was not above average.

Don’t Forget: The P/E Does Not Account For Debt or Bank Deposits

It’s important to note that the P/E ratio considers the market capitalization, not the enterprise value. So it won’t reflect the advantage of cash, or disadvantage of debt. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

While growth expenditure doesn’t always pay off, the point is that it is a good option to have; but one that the P/E ratio ignores.

How Does BioSpecifics Technologies’s Debt Impact Its P/E Ratio?

BioSpecifics Technologies has net cash of US$85m. This is fairly high at 20% of its market capitalization. That might mean balance sheet strength is important to the business, but should also help push the P/E a bit higher than it would otherwise be.

The Bottom Line On BioSpecifics Technologies’s P/E Ratio

BioSpecifics Technologies has a P/E of 19.4. That’s higher than the average in its market, which is 17.3. The excess cash it carries is the gravy on top its fast EPS growth. To us, this is the sort of company that we would expect to carry an above average price tag (relative to earnings).

When the market is wrong about a stock, it gives savvy investors an opportunity. People often underestimate remarkable growth — so investors can make money when fast growth is not fully appreciated. So this free visual report on analyst forecasts could hold the key to an excellent investment decision.

You might be able to find a better buy than BioSpecifics Technologies. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.